The Dermatology segment focuses on the development and commercialization of treatments for various skin conditions. This includes marketed products like Ximino, Targadox, Exelderm, Ceracade, Luxamend, and Accutane. Research and development activities involve clinical trials and formulation improvements for existing products, as well as exploring new therapeutic applications. The segment leverages established pharmaceutical methodologies and focuses on improving patient outcomes for acne, ringworm, dry skin, and wound management. Market positioning is enhanced by strategic partnerships and collaborations to expand product reach and market access. Future opportunities include expanding the product portfolio and exploring new indications for existing drugs. Regulatory aspects involve FDA approvals and compliance. This segment aims to provide effective and accessible dermatological solutions.

This segment focuses on advancing late-stage product candidates through clinical trials and regulatory pathways. Key projects include intravenous Tramadol for post-operative pain, CUTX-101 for Menkes disease, and various therapies for cancers and rare diseases. Research and development activities involve conducting Phase 2 and Phase 3 clinical trials, as well as manufacturing and formulation development. The segment utilizes advanced pharmaceutical technologies and methodologies to ensure product efficacy and safety. Therapeutic areas include pain management, genetic disorders, and various cancers. Patient impact is addressed by providing access to innovative treatments for unmet medical needs. Market positioning is enhanced through strategic partnerships and collaborations with research institutions and pharmaceutical companies. Future opportunities include securing regulatory approvals and commercializing these late-stage products. Regulatory aspects involve FDA submissions and compliance with clinical trial regulations. This segment aims to bring innovative therapies to market to improve patient outcomes.

This segment focuses on the discovery and development of early-stage and preclinical product candidates. Research and development activities include preclinical studies, formulation development, and early-phase clinical trials. The segment utilizes advanced technologies such as gene therapy, oligonucleotide platforms, and small molecule inhibitors. Therapeutic areas include various cancers, genetic disorders, and other diseases with high unmet medical needs. Patient impact is addressed by developing novel therapies for difficult-to-treat conditions. Market positioning is enhanced through strategic partnerships and collaborations with universities and research institutes. Future opportunities include advancing these candidates through clinical development and securing regulatory approvals. Regulatory aspects involve preclinical study requirements and early-phase clinical trial regulations. This segment aims to build a robust pipeline of innovative therapies.